key drugs guy / study tip gal

450 flashcardsby hikaru
Study these flashcardsFree · spaced repetition · iPhone, Android, Mac & web

First 300 of 450 cards

1
Extravasation due to vinca alkaloids
Warm compress & hyaluronidase
2
Chemotherapy regimen with high emetic risk (3 Options)
1. NK1-RA+ 5HT3A + Dexamethasone
2. Netupitant/palonosetron (Akynzeo) + Dexamethasone
3. Olanzapine + Palonosetron + Dexamethasone
3
Chemotherapy regimen with medium emetic risk (4 Options)
All in the high risk group +
4. 5HT-3A + Dexamethasone
4
Chemotherapy regimen with medium emetic risk (4 Options)
1. 5HT-3A
2. Dexamethasone
3. Prochlorperazine
4. Metoclopramide
5
VTE in patients with cancer
LMWH
6
Patient stopping anticoagulant post unprovoked DVT or PE
ASA if no C/I
7
VTE in patients without cancer
Dabigatran, Xaralto, Eliquis or Edoxaban
8
PCI with risk or Hx of HIT
Argatroban & Bivalirudin
9
Anticoagulant in pregnancy
Warfarin
10
Pre-meds for taxanes
H2RA + CCS (~ Dexa) + Diphenhydramine (Due to BBW hypersensitivity rxn caused by Chremephor in solvent)
11
Heparin Induced Thrombocytopenia
Argatroban (IV)
(HIT Dx: Unexplained platelet drop >50% baseline
12
DOC after HIT has resolved
Warfarin (Resolved when platelets > 150,000)
13
Antipsychotic in Parkinsons patient
Quetiapine
14
Depression in Parkinsons patient
Tricyclic - preferably seconadry amines
(desipramine or nortryptiline)
15
Bipolar with depression
Lamotrigine (not effective for acute mania)
16
Bipolar pregnant patient
Latuda (Lurasidone)
17
Bipolar manic patient
Valproate OR lithium + antipsychoticx
18
Premmenstrual dysphoric disorder
Prozac or Zoloft
19
Treponema palladium (Syphilis)
PCN G Benzathine (Bicillin L-A)

2.4 million units intramuscularly x 1 dose
(BBW: IV can cause death)
20
Neuroleptic Malignant Syndrome
1.Taper off antipsychotic
2.Cardio-resp, heme, & e-lyte support
3. Cooling bed & antipyrretics
4. BZD or Dantrolene or Bromocriptine
21
Xyrem
(4-hydroxybutanoic acid aka Sodium oxybate)
Narcolepsy with cataplexy
22
Dystonias (EPS SE)
Centrally acting anticholinergic
Benztropine or Diphenhydramine
23
Akathisia (EPS SE)
Anticholinergics
Propranolol
BZD (Lorazepam last line)
24
Tardive Dyskinesia
Can only try other agent - best quetiapine or clozapine
25
Febrile neutropenia
Merrem
26
Otitis media
Amoxicillin 80-90 mg/kg/day
or
Augmentin 90 mg/kg/day
27
Reduce mucositis and myelosuppression after High Dose MTX
Leucovorin (Fusilev)
*Required if dose > 500mg/m2
28
C. krusei and C. glabrata
Caspofungin
29
Endocarditis PFX before dental procedures
Amoxicillin

2 grams PO x 1 dose
30
Tick-borne/Rickettsial Diseases
Doxycycline
31
MRSA
Vanco

*Consider different agent if MIC >/= 2 mcg/mL
32
PFX Cardiac or vascular surgery
Cefazolin (1G) or cefuroxime (2G)

*BL allergy: Vanco or Clinda
33
PFX hip fracture repair/total joint replacement
Cefazolin

*BL allergy: Vanco or Clinda
34
PFX Colorectal & hysterectomy
Cefotetan or Cefoxitin (2Gs)

BL allergy: Clinda + (AMG or FQ or AZA)
or
Flagyl + (AMG or FQ)
35
Prevention of neurological complications of meningitis
Dexamethasone 15-20 min prior to 1st dose of abx
36
CA Acute bacterial meningitis in age < 1 month
Ampicillin* + Cefotaxime or Gentamicin

*Ampicilln for listeria coverage
37
CA Acute bacterial meningitis in age 1-23 months
Cefotaxime or Ceftriaxone + Vancomycin
38
CA Acute bacterial meningitis in 2-50 years
Cefotaxime 2g IV Q4-6H or Rocephin 2g Q12H
+
Vanco 30-45 mg/kg/day in divided doses
(Adult doses)
39
CA Acute bacterial meningitis in > 50 years or immunocompromised
Vanco + ampicillin* + (Rocephin or cefotaxime)
40
CA Acute bacterial meningitis in Pt. with severe PCN allergy
Moxi or Levofloxacin + Vanco (with or without Bactrim for listeria coverage)
41
Acute otitis media
Amoxicillin 80-90 mg/kg/day Q12H

Augmentin 90mg/kg/day Q12H
42
AOM w/ PCN allergy
Cefdinir, Cefuroxime, Cefpdoxime, or Ceftriaxone
43
AOM prevention
Prevnar 13 starting at 2 mo of age
Influenza starting >/= 6mo of age
44
Sinusitis
Augmentin
Adults x 5-7 days
Children x 10-14 days
45
Acute sinusitis > 7-10 Days
Doxycycline 100mg PO BID x 5-7 days
46
Pertussis (3 options)
1. Azithromycin 500mg x 1, then 250 mg QD x 2-5 days
2. Clarithromycin 500 mg BID or 1g ER x 7 days
3. Bactrim DS 1 tab BID x 14 days
47
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
Augmentin x 5-10 days
48
Outpatient CAP in Pt. with no ABX use in past 3 mo & previously healthy
Macrolide or doxycycline x 5 days

49
Outpatient CAP in Pt. with risk for drug resistant S.pneumoniae

1. ABX use past 3 mo
2. Chronic diseases: <3, lung, liver, renal, DM, -OHism, malignancies & asplenia
3. Immunocompromised
Two options:
1. Cefpodoxime or Cefdinir + Macrolide or doxycyclnie

2. Respiratory FQ monotherapy (G,L,orM)

x 5 days
50
Inpatient CAP
Two options:
1. BL + macrolide OR doxycycline
*Preferred BL: Ceftriaxone or Cefotaxime
*Preferred macrolide: Azithromyin

2. FQ Monotherapy (G, M, or L)

x 5 days
51
Inpatient HAP & VAP with no/low risk of MDR pathogens (target MSSA & PsA)
Zosyn
Cefepime
Levaquin
Primaxin or Merrem

x 7 days
52
Inpatient HAP & VAP targeting PsA & MRSA with no MDR risk factors
Zosyn
AZA
Cefepime
Levofloxacin
Primaxin, Merrem

+ Vanco or Linezolid

x 7 days
53
Scabies (mites)
Elimite
(Cream formulation of permethrin)
54
Urticaria (OTC & Rx)
OTC: 2G antihistamine e.g. Diphenhydramine
Rx: Hydroxyzine (Vistaril)
55
Lice
Pyrethrins (Permethrin)
56
HPV infection
Imiquimod (Aldara, Zyclara)
Inpatient HAP with high risk mortality or ABX within past 90 days
or
57
Inpatient VAP with MDR risk factors or >10% resistance to monotherapy
(Choose 2, avoid 2 BL's)
Zosyn
AZA
Cefepime, Ceftazidime
Levofloxacin
Primaxin, Merrem
Tobramycin, gentimicin, amikacin*
Colistin, polymyxin B*

+ Vanco or linezolid

x 7 days
58
Latent Tb INH treatment
INH x 9 mo. Preferred for HIV+, pregnant, & children
Rifampin x 4 month
INH and Rifapentin (Priftin) once weekly x 12 weeks
59
Active Tb
Rifampin: 10mg/kg QD
INH: 5mg/kg QD + 25 mg PO Pyridoxine
Pyrazinamide
Ethambutol

Give entire regimin x 8 weeks. If Pt. susceptible to INH and RIF d/c P&E and continue INH & RIF for 4 months
60
Endocarditis Streptococci viridans group
PCN, ampicillin, or rocephin +/- gentimicin for synergy

BL allergy: Vancomycin
61
Endocarditis Staph MSSA Endocarditis
Nafcillin or cefazolin

BL allergy: Vanco (+ gentamicin if PV)
62
Endocarditis Staph MRSA
Vanco (+ gentamicin if PV)
63
Endocarditis Enterococci
PCN or ampicillin + gentamicin for synergy

BL allergy: Vancomycin
64
IE Dental Prophylaxis
Amoxicillin 2 grams PO x 1 dose

PCN allergy: Clindamycin 600mg or
Azithro or clarithromycin 600mg

PCN allergy and NPO: Clindamycin 600mg IM/IV
65
SBP
(PEK)

Rocephin x 5-7 days
66
Mild NP SSTI (Target Streptococci)
PCN VK
Keflex
Dicloxacillin
Clindamycin

PO thx x 5 days
67
Moderate NP SSTI (Target Strep & MSSA)
PCN
Rocephin
Cefazolin
Clindamycin

IV thx x 5 days
68
Severe or necrotizing SSTI
Vanco + Beta lactam (Zosyn, Primaxin, or Merrem)
Necrotizing fascitis
69
(Target Strep pyogenes)
PCN G + Clindamycin
70
Moderate Purulent SSTI (Target CA MRSA)
Bactrim DS BID
or
Doxycycline 100 mg BID

+ I/D
71
Acute uncomplicated cystitis
Nitrofurantoin 100 mg BID w/ food x 5d
or
Bactrim 1 DS tab BID x 3d
or
Fosfomycin 3g 1 dosein 40z H20
72
Acute uncomplicated pyelonephritis in outpatient
FQ-R < 10%: PO Cipro x 7d or PO Levo x 5d

FQ-R > 10%: Rocephin 1g IV x1 or AMG IV x 1 then PO BL x 14 days
73
Acute uncomplicated pyelonephritis in hospitalized patient
Initial IV then step down to PO and treat for 14 days total
74
Bacteruria in pregnant woman
Augmentin or PO Ceph x 3-7 days
75
Urinary analgesic
Phenazopyridine
200mg x 2 days
*Take with food & 8oz H20
76
Mild-moderate CDI
1st infection
Flagyl 500mg PO TID x 10-14 days
77
Mild-moderate CDI
2nd infection (1st Recurrence)
Flagyl 500mg PO TID x 10-14 days
(same as first time therapy)
78
Mild-moderate CDI
3rd infection (2nd recurrence)
Vanco taper pulse therapy:
125 mg PO -
QID x 10-14 days
BID x 1 week
QD x 1 week
then, 125mg Q2-3d/wk x 2-8wks
79
Severe uncomplicated CDI
1st infection
Vanco 125 mg PO QID x 10-14 days
80
Severe uncomplicated CDI
2nd infection
Vanco 125 mg PO QID x 10-14 days (Same as first)
81
Severe uncomplicated CDI
3rd infection
Vanco pulse/taper therapy
82
Severe complicated disease
Vanco 500 mg PO QID + Flagyl 500 mg IV Q8H
or
*If complete ileus: Vanco per rectum 500mg in 100mL NS Q6H
83
Severe complicated disease
2nd Infection
Vanco 500 mg PO QID + Flagyl 500mg IV Q8H
84
Severe complicated disease
3rd infection
Vanco taper/pulse therapy
85
Travelers diarrhea for pregnant and children
Azithromycin 1000mg PO x1 or 500mg PO QD x 1-3 days
86
1° or 2°Syphilis (<1 yr)
Bicillin L-A!!! (PCN G BENZATHINE)
2.4 million units IM x 1
87
3° Latent syphilis (>1 yr)
Bicillin L-A
2.4 million units IM x Qwk x 3

*If pregnant desensitize and use PCN*
88
Gonorrhea
Rocephin 250 mg IM x 1 (Use Suprax 400mg PO x 1 if no Rocephin)
+
*Azithromycin 1 gram PO x 1
or
Doxycyclnie 100mg PO BID x 7 days

If using Suprax do cure test in 1 wk

:) This tx also covers chlamydia
89
Chlamydia
Azithromycin 1 gram PO x1
*Preferred for pregnancy too
90
ESBL infections
Carbapenems
91
Hypercalcemia of Malignancy
Hydration + IV bisphosphonate (Zometa)
92
Palmar-plantar erythrodysesthesia aka Hand-Foot Syndrome
No medications
93
Aspergillus
Voriconazole
94
Xerostomia
Pilocarpine (Salagen) (PO agent so can be difficult)
95
Zygomycetes
Posaconazole
*PO preferred, must be with food
96
Localized mild candida albicans (thrush) infections
Clotriamazole & Nystatin
97
Moderate-severe candida albicans (thrush) infections or HIV+
PO Fluconazole
98
Esophageal infection
Fluconazole or echinocandin
99
Invasive fungal bloodstream infection
Echinocandin
100
Nail infections
Terbinafine
101
Cryptococcus neoformans
Induction: AmphoB + flucytosine

Consolidation: Fluconazole
102
Influenza (TRMT & PFX)
Oseltamivir

TRMT: 75 mg BID x 5 days

PFX: 75mg QD x 10 days

Effective when started within 48 hour of illness.
Must be >/= 12 yo
103
Relenza Diskhaler (TRMT & PFX)
Zanamivir: Neuramidase inhibitor inhaler
(1 inhalation = 5mg)

TRMT: >/=7 yo: 10 mg BID x 5 days

PFX >/=5 yo: 10mg QD x 10 days (household) or if community outbreak x 28 days
104
Rapivab
Peramivir: Neuramidase inhibitor injectiono

600 mg IV 1xdose

*Can cause weird behavior
105
Genital herpes (HSV-2)
Acyclovir 400 mg PO three times daily (or 200 mg 5x/day)
OR Valtrex 1 g PO twice daily
OR Famvir 250 mg PO TID.

The duration of HSV-2, first episode, should be 7-10 days.
106
HSV encephalitis
IV acyclovir 10 mg/kg/dose Q8H x 14-21 dats
107
Shingles
Zovirax, Famvir, or Valtrex
108
CMV
Ganciclovir or valgancyclvoir

G: TRMT: 5mg/kg IV BID, 2PFX 5mg/kg IV QD

V: TRMT 900 mg PO BID x 21 d, 2PFX 900 mg PO QD
109
EBV (mono)
No treatment
110
OI: PCP
Bactrim DS PO QD x 21 days

*Dapsone if sulfa allergy. If giving with pyrimethamine add leucovorin to decrease myelosuppression
111
OI: T.gondii
Bactrim DS tab Daily

*Same alternative as PCP if sulfa allergy
112
OI: T.gondii encephalitis
Pyrimethamine + leucovorin +/- sulfadiazine
113
OI: MAC
Azithromycin 1,200mg PO Qwk
or
Azithromycin 600mg twice weekly
or
Clarithromycin 500 mg PO BID

+ Ethambutol
114
OI: Candidas
Fluconazole
115
OI: 2°PFX thrush
none
116
OI: 2°PFX cryptococcal meninigitis
Low dose fluconazole
117
OI: 2°PFX CMV
low dose valganciclovir
118
OI: 2°PFX MAC
same as treatment regimens
119
Low-risk patient with febrile neutropenia
PO anti-pseudomonal agents (3 options)
1. Cipro + Augmentin
2. Cipro +/- Clindamycin
3. Levofloxacin
120
High risk patient with febrile neutropenia
IV anti-PsA antibiotics (5 options)
1.Cefepime
2.Ceftazidime
3. Zosyn
4.Imipenem-cilastin
5.Merrem
121
OI: 2°PFX PCP
Bactrim or dapsone depending on sulfa allergy
122
HIV (6)
INSTI based:
Triumeq
Truvada
Descovy
Genvoya
Stribild

PI-Based:
Darunavir + ritonavir + truvada
123
PrEP
Truvada 1 tab PO QD
124
nPEP
Truvada + Dolutegravir or Raltegravir


PI-based:
Truvada + Darunavir

within 72 hours, x 28 days
125
PEP
Isentress + Truvada

Within 72 hours, x 28 days
126
HIV for pregnant women
2 NRTI + boosted-PI or INSTI

NRTI: Epzicom, Truvada, or Lamivudine

PI: Atazanavir or darunavir + ritonavir

INSTI: Raltegravir
127
Moderate-Severe Rhinitis
ICS
128
Moderate-Severe Rhinitis in pregnant woman
Budesonide (Rhinocort)
129
Bacterial Vaginosis
*Flagyl 500mg PO BID x 7 days
or
*Flagyl 0.75% gel 5g intravaginally QD x 5 days
or
Clindamycin 2% cream 5 g intravaginally HS x 7 days
130
Trichomoniasis
Flagyl (Or tinidazole) 2 grams PO x 1
*Use same for pregnancy
131
Rocky Mountain Spotted Fever
Doxycycline 100 mg PO/IV BID x 5-7 days
*Would use in child in this case*
132
Typhus
Doxycycline x 7 days
133
Lyme Disease
Doxycycline x 10-21 days
or
Amoxicillin or cefuroxime x 14-21 days
134
Pregnant - Rescue Inhaler
Albuterol
135
Pregnant - ICS
Budesonide
136
COPD Patient group A
SABA or LABA
137
COPD Patient Group B
LABA or LAMA
138
COPD Patient Group C
LAMA
139
COPD Patient Group D
LABA + LAMA
140
Thyroid Storm
PTU
141
BP in Diabetics
ACE or ARB
142
DM II
Metformin
143
Addisons Disease
Fludrocortisone
144
Desired pregnancy after discontinuation of Leflunomide (Arava)
Cholestyramine
145
RA
Methotrexate (+DMARD after bridge in moderate/severe dz)
146
SLE
Hydroxychloroquine +/- prednisone (or methylprednisonsolone) +/- Cytotoxic agent
147
MS
Copaxone +/- Interferon-beta agent
148
Raynauds
Nifedipine (DHP)
(Procardia, adalat)
149
Psoriasis
Tazorotene & Calcipotriene
150
Pressor in septic shock
Norepinephrine 0.1-1.3 mcg/kg/min
151
Extravasation
Phentolamine
152
Delirium in hospitalizatoin
Queitiapine
153
Pregnant: Morning sickness. N/V
Lifestyle
Pyridoxine (B6) +/- doxylamine
154
Pregnant: GERD
Tums
155
Pregnant: Flatululance
Simethicone
156
Pregnant: Constipation
Fiber
(Psyllium, Calcium polycarbophil, methylcellulose)
+ Lots of fluids
157
Pregnant: Cough, cold, & allergies
Chlorpheniramine (1G antihistamine)
Chronic allergy: Budesonide or Beconase AQ
*Important to use the inhaled in the first trimester*
158
Pregnant: General infection
Amoxicillin & ampicillin
Cephalosporins
Erythro & Azithromycin
159
Pregnant: Vaginal Fungal Infections
Topical OTC antifungals x 7 days
160
Pregnant: UTI
Keflex: 600mg PO Q6H x 7 day
or
Ampicillin 500mg PO Q6H x 7 days
161
Pregnant: Hyperthyroidism
Levothyroxine
Must increase dose by 30-50%
162
Pregnant: HTN
Labetalol
Methyldopa
Nifedipine
163
Diabetes
Metformin
Insulin
Glyburide
164
PCOS & Endometriosis
Combination oral contraceptives (COC)
165
Moderate-severe vasomotor symptoms in postmenopausal women
Duavee
Conjugated Estrogens & Bazedoxifene
166
Osteoporosis treatment and PFX
Bisphosphonates
167
Osteoporosis with HIGH RISK FRACTURE
Teriparatide (Forteo)
168
Topical 17-Beta-Estradiol HT (3 formulations)
Cream: Estrace - to be inserted in vagina
Ring: Estring - Q3mo
Foam: Vagifem
169
PO 17-Beta Estradiol HT
Estrace
170
Conjugated Equine Estrogens & medroxyprogesterone
PremPro & Premphase
171
Estradiol patch
Once weekly
Menostar
Climara
Given Twice Weekly:
Minivelle
Vivelle-dot
Alora
172
Estradiol Ring
Femring
173
Conjugated Equine Estrogens (3 formulations)
Premarin
Tablet, vaginal cream, and injection
174
Brisdelle
Paroxetine
For dysparenunia
175
Osphena
Dysparenunia
176
Breast CA in pre-menopausal women
Tamoxifen
177
Breast CA in post-menopausal women
Aromatase Inhibitor
178
Metastatic prostate cancer
Chemical castration
Gonadotropin release hormone agonist or antagonist
179
Chronic Myelogenous Leukemia (CML)
BCR-ABL
(Imatinib, dasatinib, nilotinib)
180
Melanoma
BRAF inhibitors, often in combination with MEK 1 and 2 inhibitors
181
Anaplastic Lymphoma Kinase Inhibitors
Crizotinib (ALK inhibitor)
182
Non-small Cell Lung Cancer
EGFR inhibitors
183
Metastatic breast cancer
Palbociclib with fulvestrant or letrozole
(Ibrance + Faslodex)
184
Acute-Acid Promyelocytic Leukemia
Tretinoin
185
Extravasation due to adriamycin
Cold compress & IV Totect
186
Extravasation due to mitomycin
Cool compress & DMSO (dimethyl sulfoxide)
187
Acute cholinergic symptoms due to Irinotecan(Flushing, diaphoresis, abdominal cramping, diarrhea)
Atropine
188
Delayed diarrhea with Irinotecan
Loperamide
*UGT1A1*28 at increased risk (also for neutropenia)
189
Post menopausal symptoms (esp. hot flashes) from SERM therapy
Venlafaxine
190
Overactive Bladder
Kegel exercises 3x/wk
191
Mild Chrons Disease
PO Budesonide
192
Mild UC
Mesalamine (5-ASA) rectal &/or PO preferred
193
Secondary prevention for patient with noncardioembolic stroke or TIA
Anti-platelet therapy:
3 options
1. Aspirin
2. Aspirin + ER dipyridamole
3. Clopidogrel
194
Secondary prevention for patient with cardioembolic stroke
Anti-coagulation therapy
195
TRMT of subarrachnoid hemmorage (SAH)
Nimodipine (Nymalize)
-highly lipophilic specific to blood vessels
-Good to pierce and squirt medication into pt mouth
-Use up to 21 days
DO NOT USE IV
196
Acne
Retinoid Topicals
(e.g. Atralin, Renova, Retin-A)
197
Severe recalcitrant nodular acne
PO isotretanoin
*causes a lot of dryness. hydrate, lip balm, eye drops*
198
Alopecia
Finasteride
Propecia
OR
Minoxidil topical OTC
199
Dandruff
Suave "dandruff"
200
Diaper rash prevention
Petrolatum ointment w/ zinc oxide
e.g. Desitin
201
Eczema
Topical steroids & HYDRATION
202
Tinea pedis, cruris, or corporis
Topical antifungal
203
HTN in non-black +/- DM (4 options)
Thiazide
CCB
ACE
ARB
204
Black +/- DM (2 options)
CCB
Thiazide
205
CKD +/- albuminuria +/- DM
ACE or ARB
206
HTN in pregnancy (3 options)
Methyldopa
Labetalol
Nifedipine ER
207
HF patient with arrhythmia
Amiodarone
208
Control ventricular rate in a patient presenting in atrial fibrillation with a rapid ventricular response
Digoxin
209
PFX nephrotoxicity due to cisplatin
Amifostine (Ethyol)
210
DM in pregnancy
lifestyle and diet modifications are recommended first, if still inadequate, insulin is tx of choice

Fasting <=95
1 hour post-meal =<140
2 hour post meal = <120
211
S/sx DM
Polyuria
Polyphagia (excessive hunger)
Polydipsia (excessive thirst)
Blurred vision
Fatigue
212
A1C to eAG
A1c of 6 is approximately 126 mg/dL

each 1% increase in A1c is equal to about 28 mg/dL

(A1c-2) x30
213
Drugs that induce hyperglycemia
Beta blockers
Diuretics
Immunosuppressants
Niacin
Protease inhibitors
Quinolones
Atypical antipsychoics
Statins
Systemic steroids
214
ADA adult non-pregnant treatment goals
A1c <7
Preprandial glucose 80-130
Postprandial glucose <180
215
Monotherapy
Lifestyle modifications + metformin

* if A1c >9 consider starting with dual therapy
*if A1c >10 and BG >300 consider stated with combination injectable therapy
216
Dual therapy
Choose one to add on:
SU
TZD
DPP-4 inhibitor
SGLT2 inhibitor
GLP-1 agonist
Basal insulin
217
Triple therapy
Most 3 drug combinations are acceptable

DO NOT USE: due to lack of studies or similar MOA
Metformin + DPP-4 + GLP-1 agonist
Metformin + SU + basal insulin

If still not working switch to injectables or add basal insulin
218
Drugs that increase/ replace insulin secretion
Insulin
SU
Meglitinides
219
Drugs that decrease hepatic glucose output
Metformin
220
Decrease glucagon which decreases glucose production
GLP-1 agnoists
DPP4-inhibitors
Pramlinitide
221
Drugs that slow gastric emptying
GLP-1 agnoists
Pramlinitide
222
Drugs that increase glucose secretion
SGLT2 inhibitors
223
Drugs that increase insulin sensitivity
TZDs
Metformin
224
Janumet
Metformin + sitagliptin
225
Qtern
Saxagliptin/dapagliflozin
226
Xultophy
Liraglutide/insulin degludec
227
Soliqua
Loxisenatide/insulin glargine
228
Metformin
Biguanide glass

Works by decrease glucose production, decrease absorption of glucose and increasing insulin sensitivity

1st line therapy in DM2

BBW: lactic acidosis, renal impairment w/ contrast dyes

C/I: eGFR <30

Do not initiate if eGFR 30-45

Monitor renal function

ER formulations can leave ghost tablet in stool

Give with a meal to decrease GI upset, N/V/D, flatulence, abdominal cramping
229
Metformin D/Is
Alcohol can increase risk for LA

Contrast media can increase risk of lactic acidosis, restarted 48 hours after procedure
230
Insulin secretagogues
SUs
Meglitinides

Stimulate insulin secretion from pancreatic beta cells to decrease postprandial blood glucose

Meglitinides have faster onset (15-60 minutes) and shorter DOA and require multiple daily dosing
231
Meglitinides
Repaglinide (15-30 minutes before meal)
Nateglinide (1-30 minutes before meal)

Warnings: hypoglycemia
SEs: weight gain
232
Sulfonylureas
Glipizide (glucotrol)
Glimepiride (Amaryl)
Glyburide

Warnings: hypoglycemia
SEs: weight gain, nausea

Glipizide IR is taken 30 minutes before a meal all others can be taken with breakfast, hold dose if pt NPO

Glucotrol XL can leave ghost tablet in stool

Glyburide is renally cleared, not preferred in renal insufficiency
233
SU/Meglitinide D/Is
Insulin, SU, and meglitinides should never be used in combination due to risk of hypoglycemia
234
Thiazolidinediones
PPAR-gamma agonists that cause increase in peripheral insulin sensitivity

Pioglitazone (actos)
Rosiglitazone)

C/I: Class 3/4 heart failure
Warnings: hepatic failure, edema

Pioglitazone: increase risk of urinary bladder tumors, do not use in pts with active bladder cancer

SEs: peripheral edema, weight gain
235
SGLT2 inhibitors
Reduce reabsorption of filtered glucose (increasing urinary glucose excretion)

Canagliflozin (invokana)
Dapagliflozin (farxiga)
Empagliflozin (jardiance)

BBW canagliflozin: increase risk of leg and foot amputations
C/I: eGFR <30

Warnings: ketoacidosis, genital mucotic infections, urosepsis, pyelonephritis, hypotension due to AKI, canagliflozin can cause hyperkalimia

SEs: weight loss
236
SGLT2 D/Is
Increased risk of intravascular volume depletion causing hypotension and AKI hen used with a diuretics, RAAS inhibitors or NSAIDS

Monitor K closely in pts on cana
237
DPP4 inhibitors
Prevent enzyme DPP-4 from breaking down incretin hormones (like GLP-1) and increase insulin release and decrease glucagon secretion

Sitagliptin (januvia)
Saxagliptin
Linagliptin
Alogliptin

Warnings: acute pancreatitis, risk of HF (saxa and alo)

Lina does not require renal dose adjustments
238
Alpha glucosidase inhibitors
Acarbose
Miglitol

Inhibit metabolism of intestinal sucrose which delays glucose absorption

Does no cause hypoglycemia but if a pt becomes hypoglycemic cannot treat with sucrose, MUST use glucose tablets or gel

Take each dose with 1st bite of meal

GI side effects are common
239
Bile acid binding resins
Colesevelam

Constipation is most common side effect
Also used for hyperlipidemia
240
Dopamide agnoists
Bromocriptine

Inhibits lactation (c/i in those breastfeeding)

Do not use with other dopamine agonists
241
GLP1 agonists
Analogs of GLP-1 which increase glucose dependent insulin secretion and decrease glucagon secretion

Exenatide (BID) & Exenatide ER (weekly)
Liraglutide (victoza) --> daily
Dulaglutide (trulicity) -->weekly
Albiglutide (tanzeum)--> weekly
Lixisenatide (adlyxin) --> daily

Warnings: pancreatitis, not recommended in pts with severe GI disease
SEs: nausea, weight loss

Slow gastric emptying and can decrease extent and rate of absorption of orally administered drugs

Can increase INR in pts on warfarin
242
Pramlinitide
Synthetic analog of amylin which helps control postprandial glucose by slowing gastric emptying

Can use in type 1 and type 2 DM

Admin SC prior to each meal

BBW: severe hypoglycemia
C/I: gastroparesis
Warnings: hypoglycemia (reduce meal time insulin by 50% when starting)
SEs: N/V, anorexia, HA, weight loss
243
Physiologic functions of insulin
Convert glucose into glycogen
Helps muscle cells take up glucose
Converts excess glucose to fat for storage in adipose tissues
244
Rapid acting insulins
Aspart (novolog)
Lispro (humalog)
Afrezza (oral inhalation powder)

Aspart/lispro
--> hypoglycemia, hypokalmia
-->SEs weight gain

Afrezza:
-->BBW acute bronchospasm
--> C/I in asthma/COPD
--> replace inhaler every 15 days

Onset within 30 minutes, peak around 1 hr, duration only a few hours
245
Short acting insulins
Regular insulin (humulin R, novolin R)
Concentrated regular insulin (U-500)

Regular: can be used in IV solutions, available w/o a prescription

U-500: 5 times as concentration (500 units/mL)
--> all pts using must be prescribed a u500 syringe, each marking represents 5 units and no dose conversions are needed
--> do not mix with any other kind of insulin

Onset within 30 minutes, peak around 3-4 hours, duration up to 12 hours
246
Intermediate acting
NPH insulins (humulin N, novolin N)

Same as rapid acting insulins plus:
Cloudy in color
Available without a prescription
Can mix with rapid or short acting insulins (clear before cloudy)

Onset within a couple hours, peak around 10 hours, duration up to 24 hours
247
Long-acting insulins
Detemir (levemir)
Glargine (Lantus)

Same as rapid acting insulins above

Onset within 4 hours, no peak, duration >24 hours
248
Pre-mixed insulins
70/30, 75/25, 50/50 (higher percent longer acting)

Given BID w/ meals according to rapid/short acting component

Humulin and novolin 70/30 are available without a prescription

NPH and protamine are cloudy
249
Initiating insulin in new type 1 TDD
TDD = 0.6 units/kg/day based on actual body weight

Divide in 2 to get basal and bolus insulin

Divide bolus insulin into 3 meals

IF using NPH and regular use 2/3 of TDD as NPH and 1/3 as regular insulin dose
250
Insulin to carb ratio (rule of 500 and 450)
Rule of 500 (rapid acting insulin)= 500/TDD = g of carbs covered by 1 unit of rapid acting insulin

Rule 450 (regular insulin)= 450/TDD= g of carbs covered by 1 unit of regular insulin
251
Correction factor/correction dose
Amount of insulin needed to return their blood glucose to a normal range (added to the dose they would normally take for that meal)

1800 rule (rapid acting)= 1800/TDD= correction factor for 1 unit for rapid acting insulin

1500 rule (regular)= 1500/TDD= correction factor for 1 unit of regular insulin

Correction dose:
(blood glucose now- target glucose)/ correction factor
252
Insulin initiation in DM2 pt
Basal insulin 0.1-0.2 units/kg/day using actual body weight, or 10 units/day

Dose is titrated 10-15% once or twice weekly to reach astinng blood glucose control
253
Insulin conversion
1:1 unit:unit conversion of TDD can be used in most cases (assuming good control)

BID NPH--> QD glargine use 80% of total NPH dose
Toujeo-->lantusasaglar use 80% of total daily toujeo dose
254
Room temp stability
Afrezza- 3 days

10 days:
--humalog 50/50 and 75/25 pens
--humulin 70/30 pens

14 days
--humulin N pen
--novolog 70/30 pen

28 days
--apidra, humalog, novolog vials and pens
--humalog 50/50 and 75/25 vials
--Novolog 70/30 vial
-humulin U500 pen
--Lantus vial/pen, basaglar pen

30 days
--humulin R u100 and 70/30 vials

40 days
humulin r u500 vial

42 days
novolin R, N and 70/30 vials
Toujeo pen
levemir vial/pen
255
Insulin pens
FlexPen: novlog products
KwikPen: humalog / humulin / basaglar
FlexTouch: levemir and tresible
SoloStart: lantus and toujeo
256
Hypoglycemia
lesss than <70 mg/dL
257
Treatment
15-20 grams of glucose/simple carbs
recheck BG in 15 minutes
If persists, repeat step 1
Once back to normal patient should eat small snack or meal
258
DKA
Type 1 diabetics

BG >250
Ketones in urine
Anoin gap metabolic acidosis
259
DKA treatment
-Fluids (start with NS when BG <250 change to D5W1/2NS)
-Regular insulin infusion (0.15 units/kg bolus then 0.1 units/kg/hr)
-Monitor potassium to prevent hypokalemia
-Give sodium bicarb if needed
260
HHS
Type 2 DM

Serum ketones are not present because DM2s have enough insulin to suppress ketogenesis

BG >600
Extreme dehydration
Altered consciousness
261
Drugs with biggest decrease in A1C
Insulin
Metformin
SUs
TZDs
GLP-1 agonists
262
Common resistant pathogens
Klebsiella pneumoniae (ESBL, CRE)
Escherichia coli (ESBL, CRE)
Acinetobacter baumanii
Enterococcus faecalis, Enterococcus faecium (VRE)
Staphylococcus aureas (MRSA)
Pseudomonas aeruginosa
263
CYP inducers
PS PORCS: phenytoin, smoking, phenobarbital, oxcarbazepine, rifampin, carbamazepine, St. John's wort
264
CYP inhibitors
G PACMAN: grapefruit, protease inhibitors, azole antifungals, cyclosporine (also cimetidine, cobicistat), macrolides (clarithro, erythro), amiodarone, non-DHP CCBs (diltiazem and verapamil)
265
List of approved drugs that can be interchanged with generics based on therapeutic equivalence
Orange Book (FDA)
266
Information on epidemiology and vaccine-preventable diseases
Pink Book (CDC)
267
News reports on regulatory, legislative, legal and business developments
Pink Sheet (Pharma Intelligence)
268
List of biological drug products, including biosimilars
Purple Book (FDA)
269
Drug pricing information
Red Book, Pharmacy
270
Summaries of pediatric infectious diseases, antimicrobial treatment and vaccinations
Red Book, Pediatrics (AAP)
271
Information of the health risks of international travel, required vaccines and prophylaxis medications
Yellow Book (CDC)
272
Information on approved animal drug products
Green Book (FDA)
273
Drugs with leaching/adsorption issues with PVC containers
Lorazepam, Amiodarone, Taxanes, Tacrolimus, Insulin, Nitroglycerin
274
Only compatible in saline
("A DIAbetic Can't Eat Pie")
Ampicillin, Daptomycin, Infliximab, Amp/Sulbactam, Caspofungin, Ertapenem, Phenytoin
275
Only compatible in dextrose
("Obese Bakers Avoid Salt")
Oxaliplatin, Bactrim, Amphotericin B, Synercid
276
Common drugs with filter requirements
*Pushy Guys (and gals) in LA LA land*

*P*henytoin
*G*olimumab

*L*ipids (1.2 micron - larger pore size filter required)
*A*mphotericin B (lipid formulations - prepare using 5 micron filter)
*L*orazepam
*A*miodarone

*Most require 0.22 micron filter during administration*

Additional drugs: *Isavuconazonium*
277
Do not refrigerate
(Dear Sweet Pharmacist, Freezing Makes Me Edgy)
Dexmedetomidine, SMX/TMP, Phenytoin, Furosemide, Moxifloxacin, Metronidazole, Enoxaparin
278
Protect from light during administration
(Protect Every Necessary Med from Daylight)
Phytonadione, Epoprostenol, Nitroprusside, Micafungin, Doxycycline
Others: Ampho B Deoxycholate, Anthracyclines, Dacarbazine, Pentamidine, Thiotepa
279
Continuous data
ratio or interval data:
ratio - age, height, weight, time BP
interval - Celsius or F temp scales
280
Discreet data
also categorical data:
nominal - gender, ethnicity, marital status, mortality
ordinal - NYHA Functional Class, pain scale
281
Type I error
false positive, the incorrect rejection of a null hypothesis, related to alpha level
found a difference when there actually is not one
282
Type II error
false negative, incorrectly accept the null hypothesis
not finding a difference when there actually is one
283
study power
The ability to detect a difference btw study groups if one actually exists.
*Indirectly related to the likelihood of making a Type II (b) error*...As power increases, chance of type II error decreases
284
interpretation of 95% confidence interval
We are 95% confident that the true population value lies somewhere between ___ and ___ (range).
285
interpretation of NNT 45
For every 45 patients who receive [treatment] for [one year], [outcome (e.g. HF progression)] is prevented in one patient
(*ROUND UP NNT* so you don't overestimate benefit)
286
interpretation of NNH 90
One additional case of [major bleeding] is expected to occur for every 90 patients taking [drug] instead of [placebo/other drug].
(*ROUND DOWN NNH* so you don't underestimate harm)
287
What kind of statistical analysis should be performed for continuous data that is normally distributed between a single group compared to known data from the population?
one-sample t-test
288
What kind of statistical analysis should be performed for before and after continuous data that is normally distributed between a single group?
dependent/paired t-test
289
What kind of statistical analysis should be performed for continuous data that is normally distributed between two groups (e.g. treatment and control comparison for BP reduction)?
unpaired student t-test
290
What kind of statistical analysis should be performed for continuous data that is normally distributed between three or more groups?
ANOVA
291
What kind of statistical analysis should be performed for discreet/categorical data between a single group or two groups (e.g. mortality data)?
Chi-square test
(Fisher's exact for a very small trial)
292
Cost-minimization analysis
used when two or more interventions have already demonstrated equivalency in outcomes and the costs of each intervention are being compared
293
cost-benefit analysis
compares the costs and benefits between unrelated or related programs, as long as the outcome is monetary
294
cost-effectiveness analysis
outcomes are measured in natural units (e.g. life years gained, mmHg blood pressure, % at treatment goal)
295
cost-utility analysis
measured in QALY
296
What is the focus of USP <797>?
minimize the risk of microorganisms or other contaminants in sterile preparations
297
What is the focus of USP <800>?
keep the compounder safe and reduce risk of exposure to the HD
298
What are the physical space basics for non-sterile compounding?
*needs to be separate and distinct from any sterile compounding
*can be performed in ambient (room) air
*must have adequate space for orderly work with shelving and storage & no storage on the floor
*needs to be adequate plumbing and 2 types of water: potable (tap water) to wash hands (along with soap and single-use towels or a hand dryer) and purified/distilled water for compounding and rinsing equipment
*well-lit, controlled HVAC, with temperature and humidity monitoring
299
What are the physical space basics for sterile compounding?
*anteroom, buffer area and a PEC (hood) with specific ISO air requirements
*all surfaces must be smooth, impervious, free from cracks or crevices and non-shedding so they are easy to clean
*walls - locked, sealed panels
*floors overlaid with wide, sheet vinyl flooring with heat-welded seams
*buffer area cannot contain sinks or floor drains
*required air and surface sampling, temp and humidity requirements to test for contaminants
300
What are the physical space basics for hazardous drugs?
*Containment*-PEC or SEC (vertical flow hood)
*permissible to perform both sterile and non-sterile HD compounding in same area as long as ISO 7 air is maintained, kept 1 meter apart, no HD powders at the same time as sterile compounding
*negative air pressure in C-SEC and C-PEC & externally exhausted or use redundant HEPA filters (* if non-sterile HD ONLY*)
*non-sterile HD ACPH 12/sterile 30

150 more cards in OutLearn. Open the full deck

Study all 450 cards for free